Hormonal
GLP-1 receptor agonists (GLP-1 RAs) produce clinically meaningful weight loss of 15–20% in clinical trials, significantly exceeding the modest 3–9% loss from alternative pharmacotherapies and the partial regain seen with lifestyle interventions alone.
GLP-1 medications like semaglutide and tirzepatide are currently the most effective pharmacological tools for weight loss, achieving 15-20% body weight reduction. They work by targeting hormonal pathways to reduce appetite and improve metabolism. While lifestyle changes (diet and exercise) are foundational, they are often insufficient alone for sustained loss. These medications are taken weekly (or daily for liraglutide) and are intended for long-term use, as stopping them typically leads to significant weight regain. They are generally recommended for individuals with a BMI of 30 or higher, or 27 or higher with related health conditions.
The approval of liraglutide, semaglutide, and tirzepatide for chronic weight management has significantly expanded their use... offering clinically meaningful weight loss of 15–20% in many clinical trials... these alternative anti-obesity medications result in modest weight loss, typically ranging from 3 to 9% of baseline body weight... On average, patients regain one-third of the weight lost (5–10% of baseline bodyweight) within the first year of treatment discontinuation
Why this rating
Supported by multiple RCTs, network meta-analyses, and large cohort studies cited in the review.
Source
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
Areesha Moiz et al. · EClinicalMedicine · 2025
DOI 10.1016/j.eclinm.2025.103363
More from this paper
- Discontinuation of GLP-1 RA treatment leads to significant weight regain (up to 68% of lost weight) and reversal of cardiometabolic improvements, indicating that obesity requires chronic management.Strong
- GLP-1 receptor agonists provide significant cardiorenal protection, reducing major adverse cardiovascular events (MACE) and kidney-related complications in patients with type 2 diabetes and/or cardiovascular disease, independent of weight loss.Strong
- GLP-1 receptor agonists are associated with a modestly increased risk of gallbladder and biliary disorders, particularly at higher doses and longer treatment durations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →